Scarica l'app Stockscreener
136.38
0.99%
-1.36
Precedente Chiudi:
$137.74
Aprire:
$137
Volume 24 ore:
628.77K
Relative Volume:
1.35
Capitalizzazione di mercato:
$8.16B
Reddito:
$354.82M
Utile/perdita netta:
$-462.76M
Rapporto P/E:
-12.05
EPS:
-11.3176
Flusso di cassa netto:
$-460.07M
1 W Prestazione:
+5.01%
1M Prestazione:
+9.65%
6M Prestazione:
+12.14%
1 anno Prestazione:
+12.56%
Intervallo 1D:
$135.61
$141.37
Intervallo di 1 settimana:
$130.00
$141.48
Portata 52W:
$111.09
$161.00
Ascendis Pharma A S Adr Stock (ASND) Company Profile
Nome
Ascendis Pharma A S Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta ASND con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ASND
Ascendis Pharma A S Adr
|
136.38 | 8.16B | 354.82M | -462.76M | -460.07M | -8.105 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ascendis Pharma A S Adr Stock (ASND) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-05 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-06-25 | Aggiornamento | TD Cowen | Hold → Buy |
| 2024-05-31 | Iniziato | Stifel | Buy |
| 2023-12-20 | Iniziato | Jefferies | Buy |
| 2023-06-14 | Ripresa | Credit Suisse | Neutral |
| 2023-04-05 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-04-04 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-03 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-10-20 | Iniziato | Goldman | Buy |
| 2022-08-30 | Ripresa | Berenberg | Buy |
| 2022-03-28 | Ripresa | Wedbush | Outperform |
| 2022-03-15 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-03-01 | Iniziato | Citigroup | Buy |
| 2022-02-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-01-06 | Iniziato | Cowen | Market Perform |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2021-10-20 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-03-30 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-03-11 | Ripresa | Stifel | Buy |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-03-20 | Iniziato | Oppenheimer | Outperform |
| 2019-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2019-03-25 | Iniziato | Evercore ISI | Outperform |
| 2019-01-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-01-24 | Aggiornamento | Leerink Partners | Mkt Perform → Outperform |
| 2018-06-26 | Iniziato | Stifel | Buy |
| 2018-04-02 | Reiterato | Leerink Partners | Mkt Perform |
| 2017-05-11 | Iniziato | JP Morgan | Overweight |
| 2017-03-09 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| 2017-02-09 | Iniziato | Credit Suisse | Outperform |
| 2016-09-26 | Iniziato | Wedbush | Outperform |
Mostra tutto
Ascendis Pharma A S Adr Borsa (ASND) Ultime notizie
Ascendis Pharma target raised to $194 on positive trial results - Investing.com
European Equities Traded in the US as American Depositary Receipts Nudge Higher Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading - MSN
European Equities Traded in the US as American Depositary Drop in Friday Trading, Down 2.8% for Week - MSN
European Equities Traded in the US as American Depositary Rise in Monday Trading - MSN
European Equities Traded in the US as American Depositary Move Higher in Monday Trading - MSN
Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug - Benzinga
TD Cowen boosts Ascendis stock target, sees Q3 Skytrofa growth lagging but long-term outlook intact - Investing.com
Nothing is Better Than Ascendis Pharma A/S ADR (ASND) stock at the moment - SETE News
Financial Health Report: Ascendis Pharma A/S ADR (ASND)’s Ratios Tell a Tale - The Dwinnex
Ascendis Pharma A/S ADR’s Banking’s 100-Day Moving Average at 134.03: Will the Stock Break Through? - The InvestChronicle
Stock Market Recap: Ascendis Pharma A/S ADR (ASND) Concludes at 132.05, a -5.10 Surge/Decline - The Dwinnex
The Ascendis Pharma A/S ADR (ASND) had a good session last reading, didn’t it? - US Post News
Stocks Showing Rising Market Leadership: Ascendis Pharma ADR Earns 83 RS Rating - Investor's Business Daily
Top investors say Ascendis Pharma A/S ADR (ASND) ticks everything they need - SETE News
Ascendis reports positive 3-year hypoparathyroidism trial data - Investing.com
Results from Ascendis Pharma A/S ADR (ASND) show risk - US Post News
Sei Investments Co. Sells 81,615 Shares of Ascendis Pharma A/S (NASDAQ:ASND) - MarketBeat
Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $191.00 - MarketBeat
Ascendis Pharma A/S (NASDAQ:ASND) Holdings Lifted by Evolutionary Tree Capital Management LLC - MarketBeat
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - MSN
Investor’s Delight: Ascendis Pharma A/S ADR (ASND) Closes Strong at 148.88, Up 1.56 - The Dwinnex
Ascendis Pharma launches $300 million public offering - Investing.com
Ascendis Pharma A/S (NASDAQ:ASND) Shares Acquired by Seven Eight Capital LP - MarketBeat
Analysts review Ascendis Pharma A/S ADR’s rating - Knox Daily
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs - Yahoo Finance
Analyzing Edgewise Therapeutics Inc (EWTX) After Recent Trading Activity - Knox Daily
Ascendis Pharma A/S ADR (ASND) did well last session? - US Post News
Ascendis Pharma shares retain Outperform rating, Evercore ISI lifts target citing potential in new patient starts - Investing.com
Prepare Yourself for Liftoff: Ascendis Pharma A/S ADR (ASND) - SETE News
Oppenheimer raises Ascendis Pharma shares, maintains Outperform rating - Investing.com India
Goldman Sachs raises Ascendis Pharma stock price target on study success - Investing.com India
Jefferies lifts Ascendis Pharma target to $179 on trial data - Investing.com
Barclays maintains BioMarin at Overweight with $110 target - Investing.com
Why This Small Biotech Is Hammering BioMarin Today - Investor's Business Daily
Positive topline data supports Ascendis Pharma stock, analyst highlights potential for weekly injection advantage. - Investing.com India
Ascendis Pharma reaffirms stock target, buy rating on study success - Investing.com
Ascendis Pharma reports growth in achondroplasia trial - Investing.com India
Citi maintains buy on Ascendis with $178 target amid trial data - Investing.com
Market Insights: Ascendis Pharma A/S ADR (ASND)’s Notable Gain of 0.78, Closing at 113.81 - The Dwinnex
Ascendis Pharma A/S ADR (ASND)’s highs and lows: A closer look at its stock price fluctuations - US Post News
Closing Figures Unveiled: Ascendis Pharma A/S ADR (ASND) Drop -1.94, Closes at 116.84 - The Dwinnex
Citi maintains Ascendis Pharma stock at Buy, positive outlook ahead of pivotal trial data - Investing.com India
A better buy-in window may exist right now for Ascendis Pharma A/S ADR (ASND) - SETE News
European Equities Traded in the US as American Depositary Receipts Flat in Monday Trading - MSN
TD Cowen maintains Buy on Ascendis, keeps $157 target - Investing.com
Ascendis Pharma A/S ADR (ASND) requires closer examination - US Post News
Stock Performance Spotlight: Ascendis Pharma A/S ADR (ASND) Ends the Day at 119.50, Down by -11.27 - The Dwinnex
Jefferies cuts Ascendis share price target amid hGH market pressure - Investing.com
Goldman Sachs cuts Ascendis Pharma shares target, maintains Buy rating - Investing.com
Ascendis Pharma A S Adr Azioni (ASND) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):